Patient Derived Xenograft PDX Models

Patient Derived Xenograft PDX Models Market Outlook

The global Patient Derived Xenograft (PDX) models market was valued at approximately USD 1.5 billion in 2023 and is projected to reach around USD 3.5 billion by 2035, growing at a compound annual growth rate (CAGR) of about 10.5% during the forecast period. The growth of this market can be attributed to increasing investments in cancer research, the rising prevalence of various cancer types, and the growing demand for personalized medicine. Additionally, advancements in genomic technologies and the ability of PDX models to closely mimic human tumors are propelling the adoption of these models in both academic and industrial research settings. As researchers seek more accurate and reliable preclinical models, the PDX market is expected to witness enhanced recognition and integration into drug development pipelines.

Growth Factor of the Market

Several factors are driving the growth of the Patient Derived Xenograft (PDX) models market. Firstly, the increasing incidence of cancer has necessitated the need for advanced research models that can accurately reflect the genetic diversity and complexity of human tumors. This has led to a growing reliance on PDX models in oncology research, as they provide more reliable preclinical data that can translate into effective clinical outcomes. Secondly, the push towards personalized medicine, where treatments are tailored to individual patients based on their tumor genetics, further emphasizes the need for PDX models that can replicate the unique characteristics of patient tumors. Additionally, the expanding pharmaceutical and biotechnology sectors are investing heavily in research and development, seeking innovative solutions like PDX models to expedite drug discovery processes. Furthermore, the global emphasis on improving clinical trial success rates and reducing the high costs associated with drug development is fueling the demand for more predictive preclinical models. Lastly, collaborations between academic institutions and industry players to enhance the understanding of tumor biology and treatment responses are also contributing to the market growth.

Key Highlights of the Market

• Increasing adoption of PDX models for personalized medicine in oncology.
• Rising investments in cancer research and drug development initiatives.
• Growth in the prevalence of various cancer types globally.
• Advancements in genomic technologies enhancing the utility of PDX models.
• Strong collaborations between academia and industry driving innovation in preclinical research.

By Tumor Type

Breast Cancer:

Breast cancer is one of the leading segments within the Patient Derived Xenograft (PDX) models market. The rising prevalence of breast cancer globally has generated a significant demand for research models that can replicate the tumor biology of this type of cancer accurately. PDX models for breast cancer allow researchers to study the efficacy of new therapeutic agents in a system that closely resembles the patient’s tumor characteristics. This segment is also driven by the continuous advancements in targeted therapies and immunotherapies aimed at improving treatment outcomes for breast cancer patients. The ability of PDX models to facilitate the understanding of tumor heterogeneity and resistance mechanisms further drives their adoption in breast cancer research.

Lung Cancer:

Lung cancer, recognized as one of the most common and deadliest cancers, is another major segment of the PDX models market. The complexity and heterogeneity associated with lung cancer necessitate robust preclinical models that accurately reflect the tumor microenvironment. PDX models provide a platform for evaluating new drugs and treatment strategies, allowing researchers to uncover insights into tumor behavior and response to therapy. As the incidence of lung cancer continues to rise, the demand for PDX models tailored to this type is expected to increase, aiding in the development of more effective therapeutic options.

Colorectal Cancer:

Colorectal cancer represents a significant portion of the PDX models market, driven by the growing understanding of the disease's biological intricacies. PDX models are instrumental in studying the efficacy of novel compounds and combination therapies for colorectal cancer, which remains a leading cause of cancer-related deaths worldwide. The use of PDX models allows for the exploration of the genetic and epigenetic factors influencing tumor progression and treatment resistance, making them invaluable tools for researchers aiming to develop personalized treatment approaches for colorectal cancer patients.

Prostate Cancer:

Prostate cancer is a prevalent cancer type, and the demand for PDX models in this area has been growing steadily. The complexity associated with the progression of prostate cancer, including hormone resistance and genetic variability, calls for sophisticated preclinical models that can effectively mimic patient tumors. PDX models are particularly useful for testing new therapies and understanding the molecular mechanisms driving prostate cancer, thus enabling the development of targeted treatment strategies. As research continues to uncover the pathways involved in prostate cancer, the reliance on PDX models is expected to enhance our understanding and treatment of this disease.

Ovarian Cancer:

Ovarian cancer, known for its late diagnosis and complex biology, is another critical segment of the PDX models market. The use of PDX models in ovarian cancer research allows scientists to investigate tumor behavior in a more representative environment, providing insights into treatment responses and resistance mechanisms. Given the challenges associated with ovarian cancer, including its heterogeneous nature and the development of chemotherapy resistance, PDX models are vital for the discovery of novel therapeutic approaches. The segment is expected to grow as researchers continue to seek effective treatments for this challenging cancer type.

By Application

Preclinical Drug Development:

The application of PDX models in preclinical drug development is one of the most significant segments in the market. These models offer a unique opportunity to evaluate the efficacy and safety of new drugs in a setting that closely resembles human tumors. PDX models help to bridge the gap between in vitro studies and clinical trials by providing more predictive data on how a drug may perform in patients. This is increasingly critical as the pharmaceutical industry seeks to enhance the success rates of clinical trials and reduce the high costs associated with drug development. As a result, the demand for PDX models in preclinical drug development is anticipated to grow steadily in the coming years.

Precision Medicine:

Precision medicine is another crucial application driving the PDX models market. The ability of these models to reflect the genetic makeup of individual tumors allows researchers to develop treatments tailored to specific patient profiles. PDX models enable the exploration of personalized therapeutic strategies, giving insights into the most effective treatment pathways for patients based on their unique tumor characteristics. As the field of precision medicine continues to evolve, the reliance on PDX models is expected to increase, fostering advancements in tailored cancer therapies and improving patient outcomes.

Oncology Research:

Oncology research represents a vital application for PDX models, facilitating the exploration of tumor biology, mechanisms of drug resistance, and potential therapeutic targets. Researchers utilize PDX models to conduct various studies that aim to enhance the understanding of cancer progression and treatment responses. These models provide a platform for testing combinations of therapies and assessing their impact on tumor growth and metastasis. As the need for innovative research methodologies in oncology intensifies, the utilization of PDX models is expected to expand, supporting the quest for more effective cancer treatments.

Personalized Medicine:

The application of PDX models in personalized medicine is becoming increasingly important, as these models allow for a more individualized approach to cancer treatment. By analyzing patient-specific tumors, researchers can identify the most effective therapies tailored to each patient's unique tumor profile. PDX models serve as a bridge between laboratory research and clinical practice, facilitating the development of personalized treatment plans. As the healthcare industry shifts towards personalized medicine, the demand for PDX models in this application is likely to surge, contributing to improved patient care and outcomes.

Toxicology Testing:

Toxicology testing using PDX models is an emerging application that holds significant promise in the market. These models provide a more accurate representation of how human tumors respond to various compounds, allowing researchers to evaluate the safety and efficacy of new drugs. By utilizing PDX models for toxicology studies, researchers can identify potential adverse effects and optimize drug formulations before advancing to clinical trials. As regulatory agencies increasingly emphasize the importance of safety assessments in drug development, the use of PDX models in toxicology testing is expected to gain momentum.

By Model Type

Mouse Models:

Mouse models are the most widely used type of PDX models in preclinical research. They provide a robust platform for studying human tumors due to their genetic and biological similarities to humans. Researchers often prefer mouse models for their ease of use, cost-effectiveness, and established protocols. As the demand for accurate preclinical data grows, mouse models continue to play a crucial role in the development of new cancer therapies and understanding tumor biology.

Rat Models:

Rat models are increasingly being utilized in the PDX models market for specific research applications. Although less common than mouse models, rat models offer distinct advantages in certain studies, such as those involving larger tumor sizes or complex surgical manipulations. Their physiological similarities to humans allow for the investigation of tumor behavior and treatment responses in a more relevant context. Rat PDX models are particularly valuable for exploring the effects of therapeutic interventions on tumor progression and metastasis.

Humanized Models:

Humanized models are gaining traction in the PDX models market due to their ability to closely mimic human immune responses. These models are engineered to include human immune cells, providing a platform for studying interactions between tumors and the immune system. Humanized PDX models are particularly valuable in cancer immunotherapy research, where understanding the immune response to tumors is crucial for developing effective treatments. The growth of the immunotherapy sector is expected to drive the demand for humanized PDX models significantly.

Canine Models:

Canine models are an emerging area of interest in the PDX models market, particularly for comparative oncology research. These models are used to study spontaneous tumors that occur in dogs, which share many similarities with human cancers. Canine PDX models provide valuable insights into tumor biology and treatment responses, as dogs often develop tumors that mimic human diseases. This segment is particularly appealing for researchers seeking to translate findings from veterinary medicine to human oncology.

Porcine Models:

Porcine models are gaining attention in the PDX models market due to their biological relevance to humans. Swine have anatomical and physiological similarities to humans, making them suitable for studying various diseases, including cancer. PDX models using porcine tumors allow researchers to explore the effects of therapies in a more complex biological system. The unique advantages of porcine models in bridging the gap between preclinical and clinical studies make them a valuable addition to the PDX landscape.

By User

Pharmaceutical & Biotechnology Companies:

Pharmaceutical and biotechnology companies represent one of the largest user segments in the Patient Derived Xenograft (PDX) models market. These organizations rely heavily on PDX models for drug discovery and development processes, utilizing them to test the efficacy and safety of new therapeutic agents. PDX models provide critical data that can inform clinical trial decisions, enabling companies to make informed choices about which candidates to advance. The growing emphasis on precision medicine and targeted therapies in the pharmaceutical industry ensures that the demand for PDX models will continue to rise in this segment.

Contract Research Organizations:

Contract Research Organizations (CROs) play a vital role in the PDX models market, offering their expertise in preclinical studies to pharmaceutical and biotechnology companies. CROs leverage PDX models to conduct research on behalf of their clients, providing valuable insights into drug efficacy and safety. As the demand for outsourcing preclinical research grows, CROs are increasingly adopting PDX models to enhance their service offerings. This segment is poised for growth as more companies recognize the benefits of utilizing CROs for efficient and effective drug development processes.

Academic & Research Institutions:

Academic and research institutions are significant users of PDX models, utilizing them for various studies aimed at understanding tumor biology and testing novel therapies. These institutions often conduct fundamental research that drives innovation in cancer treatment and improves our understanding of disease mechanisms. PDX models provide a valuable resource for researchers seeking to investigate the complexities of human tumors in a controlled environment. As funding for cancer research continues to grow, the use of PDX models in academic settings is expected to expand further.

Hospitals & Clinics:

Hospitals and clinics are increasingly adopting PDX models to support personalized medicine initiatives. These models allow clinicians to gain insights into individual patients’ tumors, facilitating the development of tailored treatment plans. As healthcare providers focus on improving patient outcomes through personalized approaches, the integration of PDX models into clinical practice is likely to increase. This segment is expected to grow as more hospitals and clinics recognize the value of such models in providing evidence-based treatment strategies.

Others:

Other users of PDX models include government agencies, nonprofit organizations, and research consortia focused on cancer research. These entities utilize PDX models to support various initiatives, ranging from basic research to translational studies aimed at improving cancer treatments. The diverse applications of PDX models across multiple sectors highlight their significance in advancing our understanding of cancer and developing effective therapies. As funding and interest in cancer research continue to grow, this segment is expected to contribute to the overall expansion of the PDX models market.

By Region

The Patient Derived Xenograft (PDX) models market exhibits significant regional variations, with North America leading this sector due to its robust healthcare infrastructure and substantial investments in cancer research. The North American market is projected to maintain a CAGR of approximately 11% through the forecast period, driven by the presence of major pharmaceutical companies, advanced research institutions, and a high prevalence of cancer. The United States, in particular, accounts for a significant share of the market as it continues to prioritize cancer research and incorporate innovative technologies like PDX models into drug development processes. The increasing focus on personalized medicine and targeted therapies is further bolstering the demand for PDX models in this region.

Europe also represents a significant market for PDX models, characterized by a growing emphasis on cancer research and precision medicine. The European PDX models market is expected to grow steadily, driven by collaborative efforts between public and private sectors focused on advancing cancer treatment options. Countries such as Germany, France, and the United Kingdom are at the forefront of oncology research, fostering an environment conducive to the development and adoption of PDX models. Additionally, the increasing number of clinical trials and investments from the European Union in health research initiatives are anticipated to further propel market growth in the region. In Asia Pacific, the expanding pharmaceutical and biotechnology sectors in countries like China and India are contributing to the increasing demand for PDX models, although the market is still in its nascent stages compared to North America and Europe.

Opportunities

One of the primary opportunities within the Patient Derived Xenograft (PDX) models market lies in the growing trend towards personalized medicine. As healthcare providers increasingly shift focus towards tailoring treatments based on individual patient characteristics, the demand for PDX models that accurately reflect tumor heterogeneity will continue to rise. The integration of genomic and molecular profiling with PDX models can enhance the understanding of how different tumors respond to specific therapies, opening avenues for novel treatment strategies. Additionally, advancements in technology, such as the development of humanized PDX models, will provide researchers with more sophisticated tools to study tumor-immune interactions, further expanding the applications of PDX models in immuno-oncology. This convergence of personalized medicine and innovative model systems presents a unique opportunity for market players to enhance their portfolios and develop cutting-edge solutions that address unmet clinical needs.

Moreover, global collaborations and partnerships between academic institutions and industry players are creating opportunities for the advancement of PDX models. Such collaborations can facilitate the sharing of knowledge and resources, leading to the development of more robust and versatile PDX models that can be utilized in various research settings. The rising prevalence of cancer and the increasing global emphasis on improving clinical trial success rates are further driving the demand for innovative preclinical models. Companies that can leverage these partnerships to enhance their PDX offerings and stay ahead of technological advancements are poised to capture a larger market share. Additionally, regulatory support for the use of PDX models in drug development could pave the way for increased adoption, making this an opportune time for stakeholders to invest in and expand their capabilities in the PDX models market.

Threats

Despite the promising growth trajectory of the Patient Derived Xenograft (PDX) models market, several threats could hinder its progress. One significant threat is the ethical and regulatory challenges associated with the use of animal models in research. Increasing scrutiny over animal welfare practices and the push for more humane alternatives may lead to restrictions on the use of certain model types, thereby impacting the adoption of PDX models. Additionally, researchers may face difficulties in obtaining suitable patient-derived tumor samples, which are crucial for developing accurate PDX models. The complexity of tumor biology and the variability in patient responses also pose challenges in ensuring that PDX models are truly representative of diverse cancer types. As the industry evolves, addressing these ethical and regulatory concerns while maintaining scientific rigor will be essential for sustained market growth.

Another potential threat to the PDX models market is the rapid advancement of alternative technologies, such as organoids and 3D cell cultures, which may offer comparable or superior insights into tumor biology without the use of animal models. These technologies are gaining traction in oncology research, and their increasing adoption could pose competition to traditional PDX models. Furthermore, the high costs associated with developing and maintaining PDX models can be a barrier for smaller research organizations and academic institutions with limited budgets. The need for continuous innovation and adaptation in response to emerging technologies and research methodologies will be vital for stakeholders in the PDX models market to remain competitive.

Competitor Outlook

• Charles River Laboratories
• Jackson Laboratory
• Inovio Pharmaceuticals
• Horizon Discovery Group
• Anticancer Inc.
• Champions Oncology
• Medical Research Council
• Covance Inc.
• UCSF Cancer Center
• OncoOne
• Genomatix Software GmbH
• Charles River Laboratories International
• Stratifyer Molecular Pathology GmbH
• Organon Pharma
• Hero Labs Inc.

The competitive landscape of the Patient Derived Xenograft (PDX) models market is characterized by numerous players actively engaged in developing and commercializing innovative research models. Key companies such as Charles River Laboratories and Jackson Laboratory are at the forefront, leveraging their extensive experience in preclinical research to offer high-quality PDX models tailored to specific cancer types. These companies have established robust pipelines and collaborations with academic and research institutions, allowing them to stay ahead of market trends and meet the evolving needs of researchers in oncology. Additionally, firms like Horizon Discovery Group and Anticancer Inc. focus on developing advanced PDX models with a particular emphasis on precision medicine and targeted therapies, further enhancing their competitive edge.

Companies such as Champions Oncology and Inovio Pharmaceuticals are also making significant strides in the PDX models market by integrating cutting-edge technologies and expanding their service offerings. Champions Oncology, in particular, has developed a comprehensive platform for PDX models that enables researchers to gain insights into tumor biology and optimize treatment strategies. With an increasing focus on personalized medicine, these players are positioning themselves as key contributors to advancing cancer research and drug development. The growing trend of partnerships between industry and academia is likely to foster innovation and enhance the capabilities of several companies, ensuring a dynamic competitive landscape in the PDX models market.

Moreover, as the market continues to evolve, newer entrants are emerging, providing unique solutions and contributing to the competitive dynamics. Companies that can effectively harness advancements in technology, such as the development of humanized and organoid models, are likely to capture significant market share. Additionally, organizations that prioritize ethical considerations and regulatory compliance will appeal to a broad range of stakeholders and enhance their reputation in the market. Overall, the competitive outlook for the PDX models market will be shaped by the ability of these companies to innovate, adapt, and meet the growing demands of cancer research.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 OncoOne
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 Covance Inc.
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 Hero Labs Inc.
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 Organon Pharma
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 Anticancer Inc.
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 Champions Oncology
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 Jackson Laboratory
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 UCSF Cancer Center
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 Inovio Pharmaceuticals
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Genomatix Software GmbH
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 Horizon Discovery Group
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Medical Research Council
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Charles River Laboratories
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Stratifyer Molecular Pathology GmbH
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Charles River Laboratories International
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Patient Derived Xenograft PDX Models Market, By User
    • 6.1.1 Pharmaceutical & Biotechnology Companies
    • 6.1.2 Contract Research Organizations
    • 6.1.3 Academic & Research Institutions
    • 6.1.4 Hospitals & Clinics
    • 6.1.5 Others
  • 6.2 Patient Derived Xenograft PDX Models Market, By Model Type
    • 6.2.1 Mouse Models
    • 6.2.2 Rat Models
    • 6.2.3 Humanized Models
    • 6.2.4 Canine Models
    • 6.2.5 Porcine Models
  • 6.3 Patient Derived Xenograft PDX Models Market, By Tumor Type
    • 6.3.1 Breast Cancer
    • 6.3.2 Lung Cancer
    • 6.3.3 Colorectal Cancer
    • 6.3.4 Prostate Cancer
    • 6.3.5 Ovarian Cancer
  • 6.4 Patient Derived Xenograft PDX Models Market, By Application
    • 6.4.1 Preclinical Drug Development
    • 6.4.2 Precision Medicine
    • 6.4.3 Oncology Research
    • 6.4.4 Personalized Medicine
    • 6.4.5 Toxicology Testing

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Middle East & Africa - Market Analysis
    • 10.5.1 By Country
      • 10.5.1.1 Middle East
      • 10.5.1.2 Africa
  • 10.6 Patient Derived Xenograft PDX Models Market by Region

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Patient Derived Xenograft PDX Models market is categorized based on

By Tumor Type

• Breast Cancer
• Lung Cancer
• Colorectal Cancer
• Prostate Cancer
• Ovarian Cancer

By Application

• Preclinical Drug Development
• Precision Medicine
• Oncology Research
• Personalized Medicine
• Toxicology Testing

By Model Type

• Mouse Models
• Rat Models
• Humanized Models
• Canine Models
• Porcine Models

By User

• Pharmaceutical & Biotechnology Companies
• Contract Research Organizations
• Academic & Research Institutions
• Hospitals & Clinics
• Others

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• Charles River Laboratories
• Jackson Laboratory
• Inovio Pharmaceuticals
• Horizon Discovery Group
• Anticancer Inc.
• Champions Oncology
• Medical Research Council
• Covance Inc.
• UCSF Cancer Center
• OncoOne
• Genomatix Software GmbH
• Charles River Laboratories International
• Stratifyer Molecular Pathology GmbH
• Organon Pharma
• Hero Labs Inc.